XML 54 R23.htm IDEA: XBRL DOCUMENT
v3.21.1

Stockholders’ Equity | 12 Months Ended
--- | ---
Jan. 02, 2021
Stockholders Equity Note [Abstract] |
Stockholders’ Equity |
Note 17: | Stockholders’ Equity
Common Stock: O ur Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. On November 4, 2020, at the Company’s Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “Charter Amendment”) to the Company’s Articles of Incorporation to increase the total number of authorized shares of the Company’s common stock from 10,000,000 shares to 200,000,000 shares. Following stockholder approval, the Charter Amendment was filed with the Nevada Secretary of State on November 5, 2020, at which time the Charter Amendment became effective. The Company’s Board of Directors had previously approved the Charter Amendment, subject to stockholder approval. The description of the Charter Amendment is qualified in its entirety by reference to the complete text of the Charter Amendment, a copy of which is filed as Exhibit 3.10 to the Company’s Quarterly Report on Form 10-Q for the period ended September 26, 2020 and is incorporated herein by reference. During fiscal year 2020, 104,798 shares of common stock were granted and issued in lieu of professional services at a fair value of $351. During fiscal year 2019, 224,483 common shares were issued as compensation to employees and consultants with a fair value of $500. Additionally, the Company recognized stock compensation expense of $54 and $131 during the years ended January 2, 2021 and December 31, 2019, respectively, related to the amortization of the fair value of shares of its common stock vesting and/or issued for services rendered. As of January 2, 2021, and December 28, 2019, there were 1,829,982 and 1,919,048 shares, respectively, of common stock issued and outstanding. Stock options: The 2016 Plan, which replaces the 2011 Plan, authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On November 4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of January 2, 2021 and December 28, 2019, 78,000 and 4,000, respectively, options were outstanding under the 2016 Plan. Our 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expires on the earlier of May 12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of January 2, 2021 and December 28, 2019, 35,900 and 40,400 options, respectively, were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan. The following table summarizes stock option activity for fiscal 2020 and 2019:
|  | Options |  |  | Weighted Average Exercise |  |  | Aggregate Intrinsic |  |  | Weighted Average Remaining Contractual |
|  | Outstanding |  |  | Price |  |  | Value |  |  | Life |
Outstanding at December 29, 2018 |  |  | 100,900 |  |  | $ | 11.07 |  |  | $ | — |  |  |  | 3.8 |
Cancelled/expired |  |  | (56,500 | ) |  |  | 9.30 |  |  |  |  |  |  |  |  |
Outstanding at December 28, 2019 |  |  | 44,400 |  |  | $ | 13.31 |  |  | $ | — |  |  |  | 3.0 |
Cancelled/expired |  |  | (4,500 | ) |  |  | 9.45 |  |  |  |  |  |  |  |  |
Granted |  |  | 74,000 |  |  |  | 3.84 |  |  |  |  |  |  |  |  |
Outstanding at January 2, 2021 |  |  | 113,900 |  |  | $ | 11.97 |  |  | $ | 78 |  |  |  | 7.0 |
Exercisable at January 2, 2021 |  |  | 65,400 |  |  | $ | 12.01 |  |  | $ | 27 |  |  |  | 3.0 |
The exercise price for stock options outstanding and exercisable outstanding at January 2, 2021 is as follows:
Outstanding |  | Exercisable
Number of Options |  |  | Exercise Price ($) |  | Number of Options |  |  | Exercise Price ($)
| 16,500 |  |  | $17.35 to $23.45 |  |  | 16,500 |  |  | $17.35 to $23.45
| 5,400 |  |  | $11.10 to $15.00 |  |  | 5,400 |  |  | $11.10 to $15.00
| 12,000 |  |  | $5.70 to $9.90 |  |  | 12,000 |  |  | $5.70 to $9.90
| 80,000 |  |  | $3.54 to $5.25 |  |  | 31,500 |  |  | $3.54 to $5.25
| 113,900 |  |  |  |  |  | 65,400 |  |  |
The following table summarizes information about the Company’s non-vested shares outstanding as of January 2, 2021 and December 28, 2019:
Non-vested Shares |  | Number of Shares |  |  | Average Grant-Date Fair Value |
Non-vested at December 29, 2018 |  |  | — |  |  | $ | — |
Granted |  |  | — |  |  | $ | — |
Vested |  |  | — |  |  | $ | — |
Non-vested at December 28, 2019 |  |  | — |  |  | $ | — |
Granted |  |  | 74,000 |  |  | $ | 3.09 |
Vested |  |  | (25,500 | ) |  | $ | 3.85 |
Non-vested at January 2, 2021 |  |  | 48,500 |  |  | $ | 3.83 |
We recognized share-based compensation expense related to stock options of $173 and $nil for fiscal years 2020 and 2019, respectively. At January 2, 2021, the Company has $55 of unrecognized compensation expense (net of estimated forfeitures) associated with stock option awards which the company expects to recognize as compensation expense through December 2021. Warrants: As of January 2, 2021 and December 28, 2019, there were 33,363 warrants outstanding to purchase 33,363 shares of common stock at a price of $3.40 per share that expire in November 2021.

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration